Qiagen (NYSE:QGEN) Stock Rating Lowered by Wall Street Zen

Qiagen (NYSE:QGEN) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

QGEN has been the topic of several other reports. Jefferies Financial Group restated a “buy” rating and issued a $59.00 price objective on shares of Qiagen in a report on Thursday, February 5th. JPMorgan Chase & Co. lifted their price target on shares of Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. TD Cowen reissued a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Finally, UBS Group set a $52.00 price objective on shares of Qiagen in a research report on Monday, February 9th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $55.20.

Qiagen Price Performance

QGEN stock opened at $39.06 on Friday. The business has a fifty day moving average of $47.70 and a two-hundred day moving average of $48.21. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The stock has a market cap of $8.05 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 1.94 and a beta of 0.70. Qiagen has a 52-week low of $38.79 and a 52-week high of $57.81.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. The business had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, research analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

A number of hedge funds and other institutional investors have recently bought and sold shares of QGEN. Danske Bank A S purchased a new stake in Qiagen during the third quarter worth about $36,000. Smartleaf Asset Management LLC boosted its stake in shares of Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after purchasing an additional 830 shares during the period. Manchester Capital Management LLC purchased a new position in shares of Qiagen in the fourth quarter valued at approximately $42,000. MAI Capital Management grew its holdings in shares of Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares in the last quarter. Finally, Global Retirement Partners LLC grew its holdings in shares of Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares in the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.